Quiz: Osteoarthritis: Pathophysiology & Treatments to Enhance Compliance

Sponsored by Boehringer Ingelheim

Canine osteoarthritis (OA) is one of the most common diseases seen by primary care veterinary teams, but it can be challenging to treat due to its chronic, progressive nature. In addition, client compliance with recommended therapies can present a major hurdle in the effective management of OA in dogs. Test your knowledge of the pathophysiology and treatment of this all-too-familiar condition.

IMPORTANT SAFETY INFORMATION

METACAM® (meloxicam oral suspension) and PREVICOX® (firocoxib) Chewable Tablets are for use in dogs only. METACAM® (meloxicam) Solution for Injection is approved for use in dogs or cats (not indicated for osteoarthritis in cats). Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. As a class, cyclooxygenase inhibitory NSAIDs like METACAM and PREVICOX may be associated with gastrointestinal, kidney, or liver side effects. Dogs should be evaluated for pre-existing conditions and currently prescribed medications prior to treatment with METACAM and PREVICOX, then monitored regularly while on therapy. Concurrent use with another NSAID, corticosteroid, or nephrotoxic medication should be avoided or monitored closely. For full prescribing information, please refer to the package inserts for METACAM Oral Suspension, PREVICOX Chewable Tablets, METACAM Solution for Injection for Dogs.

PREVICOX® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. METACAM® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trademarks are the property of their respective owner. ©2022 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0565-2021